ERBB2 and breast carcinoma: Alternative therapeutic agents for HER2-positive breast cancer range from HER2-targeted monoclonal antibodies (such as trastuzumab and pertuzumab), HER2-targeted ADCs (like T-DM1 and DS8201), and small molecule tyrosine kinase inhibitors (including lapatinib, neratinib, pyrotinib and tucatinib).